Patents by Inventor Robert Pachlinger

Robert Pachlinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220056150
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Application
    Filed: August 17, 2021
    Publication date: February 24, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk VOELKEL, Robert PACHLINGER, Hanspeter ROTTENSTEINER, Alfred WEBER, Andrea ENGELMAIER
  • Patent number: 11098132
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 24, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
  • Publication number: 20190194351
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Application
    Filed: May 16, 2017
    Publication date: June 27, 2019
    Applicants: Baxalta Incorporated, Baxalta GmbH
    Inventors: Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
  • Publication number: 20070077642
    Abstract: The present invention provides a novel steroid inducible expression system in a non-mammalian host cell (e.g., fungal) that is independent of metabolic and developmental regulation. The human estrogen receptor gene expressed in Aspergillus, under a constitutive promoter, was shown to be functional. A construct containing a promoter from Aspergillus, synthetic sequence containing the estrogen receptor biding sites (EREs) and a reporter gene was expressed in response to a hormone derivative inducer. In the absence of the inducer, the promoter is silent and depending on the type of construct and inducer concentration the expression level can be modulated from moderate to very strong.
    Type: Application
    Filed: December 23, 2003
    Publication date: April 5, 2007
    Inventors: Joseph Strauss, Robert Pachlinger